生脉散对糖尿病肾病大鼠肾脏保护作用机制的研究

Renoprotection mechanism of Shengmai powder on rats with diabetic nephropathy

目的 探讨生脉散对糖尿病肾病大鼠肾脏保护作用及机制。方法 60只SD大鼠随机分为对照组、模型组、氯沙坦钾组及生脉散低、中、高剂量组,采用腹腔注射链脲佐菌素建立大鼠糖尿病肾病模型,并给予相应药物连续治疗2周。检测大鼠糖脂代谢、24 h尿微量白蛋白、尿素、肌酐,HE染色观察肾脏病理变化,蛋白印迹法测定肾脏蛋白激酶B(Akt)、糖原合成酶激酶-3β(GSK-3β)蛋白表达。结果 与模型组比较,氯沙坦钾组、生脉散各剂量组大鼠空腹血糖、24 h尿蛋白、尿素氮、肌酐水平均降低(P<0.01或0.05),GSK-3β水平明显下调(P<0.01),Akt表达明显上调(P<0.01)。结论生脉散可通过调控Akt/GSK-3β通路,改善糖尿病大鼠肾功能。

Objective To investigate the renoprotection and mechanism of Shengmai powder(SMP) on rats with diabetic nephropathy. Methods Sixty SD rats were randomly divided into control, model, losartan, and low-, medium-and high-dose SMP groups. The diabetic nephropathy model was established by intraperitoneal streptozotocin, and each group were treated with corresponding drugs for two weeks. Glycolipid metabolism, 24-h microalbuminuria, urea, and creatinine were detected.Renal pathology and expression of Akt and glycogen synthase kinase-3β(GSK-3β) were determined by HE stain and Western blot, respectively. Results Compared with model group, fasting blood glucose, 24-h microalbuminuria, urea, creatinine, and GSK-3β expression were decreased(P<0.01 or 0.05), while Akt expression increased(P<0.01) in losartan and SMP groups.Conclusion SMP can improve renal function in rats with diabetic nephropathy through regulating Akt/GSK-3β signaling.